Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ELTX
ELICIO THERAPEUTICS, INC.
NASDAQ
$2.84
▼ DOWN 5.33% (-0.16)

KEY STATISTICS

Market Cap$54.15 M
52w High$16.00
52w Low$2.66
Dividend Yield—
Frequency—
P/E-1.31
Volume421.12K
Shares Out.19.07M

COMPANY

LEADERSHIP

Robert T. Connelly
CHIEF EXECUTIVE
Robert T. Connelly

COMPENSATION 2026

Salary$498,750
Stock Awards$0
Incentive Plan Pay$179,550
All Other Comp.$0
Total$678,300

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 5, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
33

PRICE TARGET

Target High$17.00
Target Low$17.00
Target Median$17.00
Target Consensus$17.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2023-06-02Reverse1:10

PRICE

$2.84 ▼ DOWN 5.33% (−$0.16)
OVERLAYS
$2.85$2.90$2.95$3.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.84

About Elicio Therapeutics, Inc.

https://elicio.com ↗

Elicio Therapeutics is a Boston-based clinical-stage biotech developing novel immunotherapies, including vaccines and T-cell therapies, for cancer and infectious diseases like COVID-19.

INDUSTRY

Biotechnology

A PRODUCT ELICIO THERAPEUTICS, INC. IS KNOWN FOR

ELI-002
ELI-002

ELI-002 is Elicio Therapeutics' investigational cancer vaccine targeting KRAS-mutated cancers, currently in clinical trials, aiming to prevent recurrence by stimulating the immune system to attack cancer cells.

COMPETITORS

COMPETITOR
BNTX COMPARE
MRNA COMPARE
RVMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
39
LISTED HERE
6
RANKED BY POSITION SIZE
VTI
0.00% · 415.4K
XSU.TO
0.00% · 314.6K
XRS2.F
0.00% · 11.8K
RSSL
0.00% · 6.2K
URTY
0.00% · 529
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
11.46%
HOLDERS
56
TOP 12 OF 56 · RANKED BY POSITION SIZE
Knoll Capital Management, LLC
630.9K sh · $6.74M
Vanguard Group Inc
496.9K sh · $3.96M
Balyasny Asset Management L.P.
244.8K sh · $2.62M
Geode Capital Management, LLC
135.2K sh · $1.45M
Renaissance Technologies LLC
121.6K sh · $1.3M
Susquehanna International Group, Llp
120.2K sh · $1.32M
Marshall Wace, Llp
117.2K sh · $932.91K
Millennium Management LLC
92.8K sh · $991.63K
Northern Trust Corp
59.7K sh · $638.56K
Goldman Sachs Group Inc
57.8K sh · $618.07K
683 Capital Management, LLC
56.4K sh · $603.37K
State Street Corp
50.6K sh · $541.13K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: SEE REMARKS
Shah Preetam
Purchase · 60.8K shares
2026-07-16
★
OFFICER: CHIEF SCIENTIFIC OFFICER
DeMuth Peter
Purchase · 52.8K shares
2026-07-16
★
DIRECTOR, OFFICER: CEO, PRESIDENT AND DIRECTOR
Connelly Robert
Purchase · 186.9K shares
2026-07-16
★
OFFICER: SEE REMARKS
Haqq Christopher
Purchase · 64.6K shares
2026-07-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
HOLD 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Jones Trading HOLD

SECTORS PEERS

PEERPRICE
PEPG$3.08COMPARE
CRBP$10.91COMPARE
NKTX$2.76COMPARE
MOLN$4.50COMPARE
MIST$1.16COMPARE
CRDF$0.94COMPARE
RANI$0.84COMPARE
ACTU$1.66COMPARE